{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T02:12:19Z","timestamp":1787969539921,"version":"build-2784847793"},"reference-count":38,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Mantle cell lymphoma (MCL) is a rare, incurable hematological malignancy with a heterogeneous presentation and clinical course. A wide variety of chemotherapy-based regimens are currently used in patients who are untreated. Over the last several years, several targeted or small-molecule therapies have shown efficacy in the relapsed\/refractory setting and have since been explored in the frontline setting. Lenalidomide plus rituximab was explored in a phase 2 study of 38 patients with MCL who were untreated and ineligible to receive transplantation, in which the combination produced durable remissions. We looked to build upon this regimen by adding venetoclax to the combination. We conducted a multicenter, open-label, nonrandomized, single-arm study to evaluate this combination. We enrolled 28 unselected patients with untreated disease irrespective of age, fitness, or risk factors. Lenalidomide was dosed at 20\u00a0mg daily from days 1 to 21 of each 28-day cycle. The dose of venetoclax was determined using the time-to-event continual reassessment method. Rituximab was dosed at 375\u00a0mg\/m2 weekly, starting on cycle 1, day 1 until cycle 2, day 1. No dose-limiting toxicities were noted. All patients were treated with venetoclax at the maximum tolerated dose of 400\u00a0mg daily. The most common adverse events were neutropenia and thrombocytopenia. The overall and complete response rates were 96% and 86%, respectively. In total, 86% of patients achieved minimal residual disease undetectability via next-generation sequencing. The median overall and progression-free survivals were not reached. The combination of lenalidomide, rituximab, and venetoclax is a safe and effective regimen in patients with untreated MCL. This trial was registered at www.clinicaltrials.gov as #NCT03523975.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023009992","type":"journal-article","created":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T07:03:14Z","timestamp":1680591794000},"page":"4518-4527","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":19,"title":["Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2143-9672","authenticated-orcid":false,"given":"Tycel J.","family":"Phillips","sequence":"first","affiliation":[{"name":"1Department of Hematology and Bone Marrow Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0773-1829","authenticated-orcid":false,"given":"David","family":"Bond","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radihka","family":"Takiar","sequence":"additional","affiliation":[{"name":"3Division of Hematology-Oncology, The University of Michigan Rogel Cancer Center, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karson","family":"Kump","sequence":"additional","affiliation":[{"name":"3Division of Hematology-Oncology, The University of Michigan Rogel Cancer Center, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malalthi","family":"Kandarpa","sequence":"additional","affiliation":[{"name":"3Division of Hematology-Oncology, The University of Michigan Rogel Cancer Center, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Boonstra","sequence":"additional","affiliation":[{"name":"3Division of Hematology-Oncology, The University of Michigan Rogel Cancer Center, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tera Lynn","family":"Mayer","sequence":"additional","affiliation":[{"name":"3Division of Hematology-Oncology, The University of Michigan Rogel Cancer Center, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Nachar","sequence":"additional","affiliation":[{"name":"3Division of Hematology-Oncology, The University of Michigan Rogel Cancer Center, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6420-0760","authenticated-orcid":false,"given":"Ryan A.","family":"Wilcox","sequence":"additional","affiliation":[{"name":"3Division of Hematology-Oncology, The University of Michigan Rogel Cancer Center, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2286-8014","authenticated-orcid":false,"given":"Shannon A.","family":"Carty","sequence":"additional","affiliation":[{"name":"3Division of Hematology-Oncology, The University of Michigan Rogel Cancer Center, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2648-4448","authenticated-orcid":false,"given":"Yasmin H.","family":"Karimi","sequence":"additional","affiliation":[{"name":"3Division of Hematology-Oncology, The University of Michigan Rogel Cancer Center, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6688-4206","authenticated-orcid":false,"given":"Zaneta","family":"Nikolovska-Coleska","sequence":"additional","affiliation":[{"name":"3Division of Hematology-Oncology, The University of Michigan Rogel Cancer Center, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Kaminski","sequence":"additional","affiliation":[{"name":"3Division of Hematology-Oncology, The University of Michigan Rogel Cancer Center, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9665-7415","authenticated-orcid":false,"given":"Alex F.","family":"Herrera","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Bone Marrow Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kami","family":"Maddocks","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8418-2811","authenticated-orcid":false,"given":"Leslie","family":"Popplewell","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Bone Marrow Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey V.","family":"Danilov","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Bone Marrow Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,8,11]]},"reference":[{"issue":"9","key":"2023082115042438200_bib1","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.24086","article-title":"Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011","volume":"90","author":"Al-Hamadani","year":"2015","journal-title":"Am J Hematol"},{"issue":"1","key":"2023082115042438200_bib2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","article-title":"Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era","volume":"117","author":"Perez-Galan","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2023082115042438200_bib3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"2023082115042438200_bib4","first-page":"285","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2017","edition":"ed 4"},{"issue":"4","key":"2023082115042438200_bib5","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1182\/blood-2018-03-838136","article-title":"A\u00a0gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome","volume":"132","author":"Clot","year":"2018","journal-title":"Blood"},{"issue":"15","key":"2023082115042438200_bib6","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1002\/cncr.30068","article-title":"Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma","volume":"122","author":"Cohen","year":"2016","journal-title":"Cancer"},{"issue":"4","key":"2023082115042438200_bib7","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/0008-5472.CAN-09-3419","article-title":"Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma","volume":"70","author":"Fernandez","year":"2010","journal-title":"Cancer Res"},{"issue":"8","key":"2023082115042438200_bib8","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","article-title":"Outcome of deferred initial therapy in mantle-cell lymphoma","volume":"27","author":"Martin","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2023082115042438200_bib9","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2011-09-370320","article-title":"CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte","volume":"121","author":"Delarue","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2023082115042438200_bib10","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14241","article-title":"15-year follow-up of the second nordic mantle cell lymphoma trial (MCL2): prolonged remissions without survival plateau","volume":"175","author":"Eskelund","year":"2016","journal-title":"Br J Haematol"},{"issue":"12","key":"2023082115042438200_bib11","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1200\/JCO.18.00605","article-title":"First-line treatment of patients with indolent non-hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study","volume":"37","author":"Flinn","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2023082115042438200_bib12","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in\u00a0vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"issue":"10044","key":"2023082115042438200_bib13","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","article-title":"Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"2023082115042438200_bib14","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"2023082115042438200_bib15","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","volume":"377","author":"Le Gouill","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"9873","key":"2023082115042438200_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial (vol 381, pg 1203, 2013)","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"30","key":"2023082115042438200_bib17","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"29","key":"2023082115042438200_bib18","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II mcl-001 (EMERGE) Study","volume":"31","author":"Goy","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2023082115042438200_bib19","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2141.2009.07626.x","article-title":"Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma","volume":"145","author":"Habermann","year":"2009","journal-title":"Br J Haematol"},{"issue":"7","key":"2023082115042438200_bib20","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.3324\/haematol.2011.041392","article-title":"Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma","volume":"96","author":"Lamm","year":"2011","journal-title":"Haematologica"},{"issue":"3","key":"2023082115042438200_bib21","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1470-2045(15)00559-8","article-title":"Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial","volume":"17","author":"Trn\u011bn\u00fd","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6","key":"2023082115042438200_bib22","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","article-title":"Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"issue":"6","key":"2023082115042438200_bib23","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"2023082115042438200_bib24","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1182\/blood-2018-07-859769","article-title":"Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma","volume":"132","author":"Ruan","year":"2018","journal-title":"Blood"},{"issue":"19","key":"2023082115042438200_bib25","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","article-title":"Lenalidomide plus rituximab as initial treatment for mantle-cell Lymphoma","volume":"373","author":"Ruan","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2023082115042438200_bib26","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","article-title":"Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial","volume":"13","author":"Wang","year":"2012","journal-title":"Lancet Oncol"},{"issue":"2","key":"2023082115042438200_bib27","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"issue":"17","key":"2023082115042438200_bib28","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-20-4842","article-title":"Long-term follow-up of patients with relapsed or refractory non-Hodgkin lymphoma treated with venetoclax in a phase i, first-in-human study","volume":"27","author":"Davids","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2023082115042438200_bib29","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2023082115042438200_bib30","doi-asserted-by":"crossref","first-page":"E68","DOI":"10.3324\/haematol.2018.198812","article-title":"Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy","volume":"104","author":"Eyre","year":"2019","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2023082115042438200_bib31","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood-2020-133273","article-title":"Venetoclax, lenalidomide and rituximab for patients with relapsed or refractory mantle cell lymphoma - data from the nordic lymphoma group NLG-MCL7 (VALERIA) phase 1 trial: stopping treatment in molecular remission is feasible","volume":"136","author":"Jerkeman","year":"2020","journal-title":"Blood"},{"issue":"7","key":"2023082115042438200_bib32","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood.2020008727","article-title":"Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1\/2 trial","volume":"137","author":"Le Gouill","year":"2021","journal-title":"Blood"},{"issue":"13","key":"2023082115042438200_bib33","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2023082115042438200_bib34","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/bjh.12633","article-title":"AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenstrom macroglobulinaemia","volume":"164","author":"Paulus","year":"2014","journal-title":"Br J Haematol"},{"issue":"4","key":"2023082115042438200_bib35","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/j.0006-341X.2000.01177.x","article-title":"Sequential designs for phase I clinical trials with late-onset toxicities","volume":"56","author":"Cheung","year":"2000","journal-title":"Biometrics"},{"issue":"1","key":"2023082115042438200_bib36","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2307\/2531628","article-title":"Continual reassessment method - a practical design for phase-1 clinical-trials in cancer","volume":"46","author":"O'Quigley","year":"1990","journal-title":"Biometrics"},{"issue":"21","key":"2023082115042438200_bib37","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2023082115042438200_bib38","first-page":"141","article-title":"An empirical transition matrix for non-homogeneous Markov chains based on censored observations","volume":"5","author":"Aalen","year":"1978","journal-title":"Scand J Stat"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/16\/4518\/2072622\/blooda_adv-2023-009992-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/16\/4518\/2072622\/blooda_adv-2023-009992-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T11:07:36Z","timestamp":1692616056000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/16\/4518\/495202\/Adding-venetoclax-to-lenalidomide-and-rituximab-is"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,11]]},"references-count":38,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2023,8,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023009992","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,11]]}}}